Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Post by DJDawgon Feb 11, 2024 8:54am
296 Views
Post# 35874327

GBM

GBM
One huge challenge with recruiting patients for NMIBC is that you are competing for patients with other studies. If you look at the number of patients treated by IBRX and CGON in relation to the number of recruitment sites it is quite the ratio. They too have a huge number of sites but the number of total patients they get is not that impressive.

When TLT gets going on GBM they won't have quite the same challenge. There is so little out there to offer GBM patients sadly. Since they are based in TO they would almost certainly do the phase 1a/b out of that city. If you look at clinicaltrials.gov the number of GBM studies being run out of Toronto are very few and most don't apply unless you have some highly specific criteria. That is why GBM patients have such a hard time, there is so little out there.

So, for future reference, when they go to GBM they may have a faster go at getting patients and results compared to NMIBC.
<< Previous
Bullboard Posts
Next >>